SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 270 filers reported holding SAGE THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,414,978 | +17.2% | 68,755 | +167.7% | 0.08% | +20.0% |
Q2 2023 | $1,207,427 | -7.6% | 25,679 | -17.5% | 0.06% | -19.8% |
Q1 2023 | $1,306,802 | +173.4% | 31,144 | +170.7% | 0.08% | +200.0% |
Q2 2020 | $478,000 | +70.7% | 11,507 | +18.1% | 0.03% | +28.6% |
Q1 2020 | $280,000 | -70.8% | 9,741 | -26.7% | 0.02% | -50.0% |
Q4 2019 | $959,000 | -42.5% | 13,288 | +11.8% | 0.04% | -50.0% |
Q3 2019 | $1,668,000 | -27.7% | 11,887 | -5.7% | 0.08% | -22.9% |
Q2 2019 | $2,307,000 | +3.6% | 12,600 | -10.0% | 0.11% | +1.9% |
Q1 2019 | $2,226,000 | +80.7% | 13,993 | +8.8% | 0.11% | +40.8% |
Q4 2018 | $1,232,000 | -45.4% | 12,866 | -19.4% | 0.08% | -11.6% |
Q3 2018 | $2,255,000 | – | 15,967 | – | 0.09% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Casdin Capital, LLC | 312,000 | $29,886,000 | 5.11% |
DAFNA Capital Management LLC | 104,306 | $9,991,000 | 4.97% |
Palo Alto Investors LP | 850,977 | $81,515,000 | 4.34% |
BB BIOTECH AG | 1,375,229 | $131,733,000 | 4.22% |
Eventide Asset Management | 936,000 | $89,659,000 | 3.97% |
TRV GP II, LLC | 37,362 | $3,579,000 | 3.56% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 146,179 | $14,002,000 | 2.11% |
SUFFOLK CAPITAL MANAGEMENT LLC | 111,908 | $10,720,000 | 2.06% |
OAK RIDGE INVESTMENTS LLC | 231,483 | $22,174,000 | 1.60% |
Rhenman & Partners Asset Management AB | 137,339 | $13,156,000 | 1.50% |